Beta Bionics, Inc.
Submit Your Information
If you suffered a loss on your Beta Bionics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.
Background
On January 8, 2026 Beta Bionics reported an unexpected miss to new iLet patient starts.
On this, Beta Bionics shares fell $11.85 or 37.04%, to close at $20.14 per share on January 9, 2026, thereby injuring investors.
Then, on January 30, 2026, Beta Bionics' disclosed it had received a warning letter from the FDA related to a Form 483 (inspectional observations), including issues beyond mere complaint handling.
On this, Beta Bionics shares fell $0.96, or 6.5%, to close at $13.83 per share on January 30, 2026.
Finally, on February 24, 2026, the FDA publicly released a warning letter detailing a litany of violations and the Company’s failure to correct them. The warning letter made clear that the Company’s prior interpretation of FDA reporting requirements had not been reasonable and had excluded numerous serious patient incidents that clearly should have been reported.
On this news, Beta Bionics, Inc. stock price fell $0.50 or 3.73%, to close at $12.89 on February 25, 2026, thereby injuring investors further.
Submit Your Information